Results 251 to 260 of about 154,650 (346)

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff   +3 more
wiley   +1 more source

Emerging insights into amino acid metabolism in the heart: implications for cardiovascular diseases and therapeutic targeting

open access: yesBritish Journal of Pharmacology, EarlyView.
As a metabolically versatile organ, the heart is capable of generating energy from a wide range of substrates. Although fatty acid and glucose metabolism in the heart have been extensively studied, the contribution of amino acid metabolism to cardiac physiology and disease is gaining increasing attention.
Tayyiba Azam   +6 more
wiley   +1 more source

A20 Inhibits IFN‐γ Signaling in Hepatocellular Carcinoma Cells by Binding to STAT1, Compromising Anti‐Tumor Immunity

open access: yesCancer Science, EarlyView.
A20 suppresses IFN‐γ signaling in HCC cells by binding to STAT1 through its ZnF7 domain, thereby reducing CXCL9, CXCL10, and HLA‐ABC expression, ultimately impairing CD8+ T‐cell‐mediated anti‐tumor immunity. ABSTRACT Immune checkpoint blockade (ICB) has demonstrated efficacy in clinical cancer therapy; however, a significant proportion of cancer ...
Yanlei Dong   +14 more
wiley   +1 more source

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet   +3 more
wiley   +1 more source

CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3. [PDF]

open access: yesFASEB J
Hamad RS   +17 more
europepmc   +1 more source

Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study. [PDF]

open access: yesMedicine (Baltimore)
Khan SA   +12 more
europepmc   +1 more source

Reduced Risk of MASLD and Cardiometabolic Disease Following Renal Denervation Therapy in Patients With Resistant Hypertension

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Autonomic dysfunction increases the risk of cardio‐kidney‐metabolic (CKM) syndrome including metabolic dysfunction‐associated steatotic liver disease (MASLD), type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD).
Alex E. Henney   +8 more
wiley   +1 more source

Thermoneutrality Accelerates a Distinctive Metabolic Dysfunction-Associated Steatohepatitis Phenotype in a Diet-Induced Male Mouse Model With Similarities to Human Disease. [PDF]

open access: yesCell Mol Gastroenterol Hepatol
Leke R   +13 more
europepmc   +1 more source

GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To critically examine the evolving evidence on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and the dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonist tirzepatide as adjuncts to insulin therapy in type 1 diabetes (T1D), with particular emphasis on their benefit–risk balance in individuals with ...
Thales Rossatto   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy